Cardiff Oncology, Nerviano Medical Sciences expand onvansertib collaboration under amended license agreement

• Cardiff Oncology reached a settlement with Nerviano Medical Sciences, amending their 2017 exclusive license for onvansertib.
• Amendment expands collaboration to support clinical development, targeting a global Phase 3 study in first-line RAS-mutated metastatic colorectal cancer.
• Parties agreed to mutual releases, planning to seek dismissal with prejudice of all claims in U.S. litigation.
• Updated deal clarifies and expands royalties, granting Nerviano rights to appoint a board observer, join the scientific advisory board.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-042506), on September 14, 2026, and is solely responsible for the information contained therein.